Shares of Mako Surgical (NSDQ:MAKO) are down 6.6 percent since the robotic surgery firm reported wider third-quarter losses, despite a nearly 67 percent increase in sales.
Mako reported losses of $9.7 million, or 24 cents per share, on sales of $20.0 million during the three months ended Sept. 30.
The wider losses – which missed Wall Street analysts’ expectations of 22 cents by two pennies – sent MAKO shares down 6.6 percent, to $33.50, as of about 10:10 this morning. The stock lost 7.0 percent yesterday, falling to a $33.34 close.
Sign up to get our free newsletters delivered right to your inbox
"We are pleased with our strong operating results in the third quarter of 2011, including the commercial introduction of MAKOplasty Total Hip Arthroplasty," president & CEO Dr. Maurice Ferre said in prepared remarks. "We believe that the expansion of our product offering through the launch of the hip application will allow us to continue to drive the adoption of MAKOplasty to help enable surgeons to deliver consistent, reproducible precision to orthopedic procedures."
CFO Fritz LaPorte told analysts on a conference call that the company reaffirmed its prediction that it will sell between 44 and 48 of its Rio systems this year.
"We also expect that by year end at least one-third of our installed base will include the hip application, either through upgrades or new sales," LaPorte added. "As for MAKOplasty procedures, we are narrowing our range of guidance and now expect that our customers will perform 6,600 to 6,900 procedures in 2011."
MassDevice keeps a close eye on public medical device companies, tracking their quarterly sales and earnings reports. For the most recent filings, check out our Earnings Roundup.
Unilife’s FY2012 Q1 sales, losses rise
First-quarter sales for fiscal 2012 fell nearly 40 percent and losses rose 34 percent for Unilife (NSDQ:UNIS).
The drug-delivery systems maker reported losses of $9.7 million, or 16 cents per share, on sales of $2.1 million for the three months ended Sept. 30.
That compares with losses of $7.2 million, or 14 cents per share, on sales of $`3.5 million during the same period last year. Read more
Elron’s Q3 sales soar, losses rise
Third-quarter sales for Elron Electronic Industries rose by a whopping 208 percent, but losses widened 17 percent.
The Israeli company, which owns stakes in several medical device firms, reported losses of $5.3 million, or 19 cents per share, on sales of $15.8 million during the three months ended Sept. 30.
That compares with losses of $4.5 million, or 17 cents per share, on sales of $5.1 million during the same period last year. Read more
Dusa’s Q3 profits skyrocket
Third-quarter sales for Dusa Pharmaceuticals (NSDQ:DUSA) skyrocketed by 10,584 percent on a 17.9 percent sales increase.
The drug-device combination maker logged profits of $3.5 million, or 13 cents per share, on sales of $9.4 million during the three months ended Sept. 30.
That compares with profits of $33,000, or no cents per share, on sales of $8.0 million during the same period last year. Read more
Angiotech’s Q3 sales slip, losses tick up
Angiotech Pharmaceuticals (PINK:ANPI), which makes the paclitaxel used in some Boston Scientific (NYSE:BSX) drug-eluting stents, reported a 2.7 percent sales decrease and a 1 percent increase in losses for the third quarter.
The firm posted losses of $18.7 million, or $1.47 per share, on sales of $57.4 million during the three months ended Sept. 30.
That compares with losses of $18.5 million, or 22 cents per share, on sales of $59.0 million during the same period last year. Read more
Q3 sales, losses mount for Syneron
Syneron (NSDQ:ELOS) boosted the top line by 28.2 percent but saw losses widen by 663 percent during the third quarter.
The Israeli cosmetic device maker logged losses of $40.1 million, or $1.14 per share, on sales of $567.0 million during the three months ended Sept. 30.
That compares with losses of $5.3 million, or 15 cents per share, on sales of $44.4 million for the same period last year. Read more
VirtualScopics’ Q3 sales, profits slide
Third-quarter sales for VirtualScopics dropped 9.0 percent and profits dipped 6.3 percent.
The clinical trial imaging firm reported profits of $551,000, or 2 cents per share, on sales of $3.3 million for the three months ended Sept. 30.
That compares with profits of $588,000, also 2 cents per share, on sales of $3.6 million during the same period last year. Read more
